Superworth

Puma Biotechnology price to free cash flow PBYI

Market value divided by free cash flow over the last twelve months, since 2025.

Today, Nov 2, 2026
12.8×
Peer median
7.5×

Puma Biotechnology's price to free cash flow is 12.8× as of Nov 2, 2026.

The median for 10 large drugmakers of a similar size is 7.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.8×6.6×13.8×
20257.2×4.2×7.2×

Against its peers

Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Puma Biotechnology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.